PHXM Share Price Performance
€0.10
-1.70 (-94.42%)
Price €0.10
Share Price€0.10
PHAXIAM Therapeutics S.A. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
PHXM Community Narratives
There are no narratives available yet.
Recent PHXM News & Updates
PHAXIAM Therapeutics S.A. Key Details
Last Reported Earnings
Jun 30, 2024
Next Reporting Earnings
Sep 24, 2025
- Earnings per share (EPS)
- -2.18
- Gross Margin
- 100.00%
- Net Profit Margin
- -1,023.91%
- Debt/Equity Ratio
- 51.8%
PHAXIAM Therapeutics S.A. Competitors
Snowflake Analysis
About PHXM
- Founded
- 2004
- Employees
- 68
- CEO
- WebsiteView website
PHAXIAM Therapeutics S.A., a clinical-stage biopharmaceutical company, focuses on developing bacteriophage-based therapies for severe resistance infections in France. The company develops and commercializes red cell-based therapies for cancers and orphan diseases. It develops anti-infectious therapies based on the use of bacteriophages (phages) to treat infections caused by Escherichia coli (E.coli), Pseudomonas aeruginosa (P.aeruginosa), and Staphylococcus aureus (S.aureus). The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. The company was incorporated in 2004 and is headquartered in Lyon, France.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
French Market Performance
- 7 Days: 1.6%
- 3 Months: 1.3%
- 1 Year: 5.2%
- Year to Date: 7.3%
Over the last 7 days, the market has risen 1.6%, driven by gains of 6.5% in the Consumer Discretionary sector. In the last year, the market has climbed 5.2%. Earnings are forecast to grow by 12% annually. Market details ›